Products for Research Use Only
RegisterLogin

Rel-Talmapimod (hydrochloride)

CAT: 0804-HY-10406BSize: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-10406BSize:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Rel-Talmapimod (rel-SCIO-469) hydrochloride is an orally active and selective inhibitor of p38α MAPK with an IC50 of 9 nM. rel-Talmapimod hydrochloride inhibits the secretion of inflammatory factors (such as TNFα, IL-1β, IL-6, and VEGF) by suppressing the p38α MAPK pathway, and it also inhibits angiogenesis and osteoclast activation. rel-Talmapimod hydrochloride inhibits the growth of multiple myeloma cells and induces apoptosis. rel-Talmapimod hydrochloride can be used to study various hematological malignancies (such as multiple myeloma, myelodysplastic syndrome) [1][2][3][4].
CAS Number
879132-01-1
Product Name Alternative
Rel-SCIO-469 (hydrochloride)
UNSPSC
12352005
Target
Apoptosis; Interleukin Related; p38 MAPK; TNF Receptor; VEGFR
Related Pathways
Apoptosis; Immunology/Inflammation; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Smiles
CN(C)C(C(C(C1=C2)=CN(C)C1=CC(Cl)=C2C(N3[C@@H](CN([C@H](C3)C)CC4=CC=C(C=C4)F)C)=O)=O)=O.Cl
Molecular Formula
C27H31Cl2FN4O3
Molecular Weight
549.46
References & Citations
[1]Hideshima T et al. p38 MAPK inhibition enhances PS-341 (bortezomib) -induced cytotoxicity against multiple myeloma cells. Oncogene. 2004 Nov 18, 23 (54), 8766-76.|[2]Navas T, et al. Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment. Leuk Lymphoma. 2008 Oct;49 (10) :1963-75.|[3]Vanderkerken K et al. Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma. Cancer Res. 2007 May 15;67 (10) :4572-7.|[4]Medicherla S, et al. p38alpha-selective MAP kinase inhibitor reduces tumor growth in mouse xenograft models of multiple myeloma. Anticancer Res. 2008 Nov-Dec;28 (6A) :3827-33.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
IL-1; IL-6; p38α; p38β

Related Products

CatalogName
HY-10406ATalmapimod (hydrochloride)
HY-10406-01Talmapimod
HY-101512DRel-A-395 (hydrochloride)
HY-10121DRel-Asenapine (hydrochloride)
HY-18617Rel-SB-612111 (hydrochloride)
HY-B0481SRel-Miglitol-d4 (hydrochloride)
HY-B0176ASRel-Sertraline-d3 (hydrochloride)
HY-151216SRel-Paroxetine-d4 (hydrochloride)
HY-13047ARel-S- (+) -Mecamylamine (hydrochloride)
HY-123059S(rel) -Zenidolol -d7 (hydrochloride)

Alternative Products

CatalogName
GTR19204823-01Talmapimod hydrochloride
166303Rel-Desethylreboxetine Hydrochloride
TRC-V128903-500MGrel-Vesamicol Hydrochloride
GTR19264280-01Rel-A-395 hydrochloride
T12701-01(rel) -Tranylcypromine D5 hydrochloride
MBS5767480(rel)-Tranylcypromine D5 hydrochloride
166304Rel-Desethylreboxetine-d4 Hydrochloride
GTR19200856-01Rel-SB-612111 hydrochloride
T84393-01Rel-HDMP 28 hydrochloride
TRC-T712540-50MGrel (1R,2S)-Tramadol Hydrochloride

Popular Products